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Glioblastoma, the most common malignant primary brain tumor in adults is a devastating
diagnosis with an average survival of 14–16 months using the current standard of care
treatment. The determination of treatment response and clinical decision making is based
on the accuracy of radiographic assessment. Notwithstanding, challenges exist in the
neuroimaging evaluation of patients undergoing treatment for malignant glioma. Differen-
tiating treatment response from tumor progression is problematic and currently combines
long-term follow-up using standard magnetic resonance imaging (MRI), with clinical status
and corticosteroid-dependency assessments. In the clinical trial setting, treatment with
gene therapy, vaccines, immunotherapy, and targeted biologicals similarly produces MRI
changes mimicking disease progression. A neuroimaging method to clearly distinguish
between pseudoprogression and tumor progression has unfortunately not been found
to date. With the incorporation of antiangiogenic therapies, a further pitfall in imaging
interpretation is pseudoresponse.The Macdonald criteria that correlate tumor burden with
contrast-enhanced imaging proved insufficient and misleading in the context of rapid blood–
brain barrier normalization following antiangiogenic treatment that is not accompanied by
expected survival benefit. Even improved criteria, such as the RANO criteria, which incor-
porate non-enhancing disease, clinical status, and need for corticosteroid use, fall short of
definitively distinguishing tumor progression, pseudoresponse, and pseudoprogression.
This review focuses on advanced imaging techniques including perfusion MRI, diffusion
MRI, MR spectroscopy, and new positron emission tomography imaging tracers.The rele-
vant image analysis algorithms and interpretation methods of these promising techniques
are discussed in the context of determining response and progression during treatment of
glioblastoma both in the standard of care and in clinical trial context.
Keywords: glioblastoma, pseudoprogression, pseudoresponse, antiangiogenic therapy, Immunotherapy, imaging
techniques
CURRENT CHALLENGES IN POST-TREATMENT IMAGING OF
GLIOBLASTOMA
Glioblastoma, the most common malignant primary tumor of the
central nervous system, carries a dismal prognosis with an aver-
age median survival of 14–16 months (1, 2). This has remained
largely unchanged in the last decades, despite increased under-
standing of molecular pathogenesis and tumor microenvironment
(3, 4). The current standard of care for newly diagnosed GBM
consists of maximal safe resection followed by 60 Gy fractionated
radiotherapy plus continuous daily temozolomide and then 6–12-
month cycles of adjuvant temozolomide (5, 6). At progression,
bevacizumab is the mainstay of treatment, more recently with the
addition of CCNU (7).
Therapeutic strategies to date include intensified chemotherapy
regimens, targeting distinct molecular pathways, inhibiting angio-
genesis, and more recently immunotherapy (8). Despite these
efforts, very few agents have been approved for the treatment of
glioblastoma aside from temozolomide for patients with newly
diagnosed GBM and bevacizumab for patients with progressive
disease (PD) (5, 9). The molecular and biological complexity of
GBM, its inherent adaptability and poor response to treatment,
redundancy of signaling pathways, as well as the poor penetration
of therapeutic agents through the blood–brain barrier (BBB) all
contribute to poor progress in approval of effective therapeutics
(9). A major road-block to assessment and development of effec-
tive therapeutics, however, is the lack of reliable trial endpoints
(9). While overall survival (OS) is the gold standard in assess-
ment of efficacy, progression-free survival (PFS) and response
rate (RR) are valuable endpoints, highlighting the relative ben-
efit of a given therapy and facilitating effective drug development
(6, 10). Response and progression endpoints rely on magnetic res-
onance imaging (MRI) and are fraught with challenges including
variability in image acquisition parameters, inter-rater measure-
ment variability, difficulty in measurement of irregularly shaped
tumors, and consistent interpretation of treatment-related radi-
ographic changes: pseudoprogression secondary to radiation and
chemotherapy, as well as pseudoresponse with antiangiogenic
therapy (6, 9).
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Current radiographic assessment of glioblastoma is based on
MRI, with extent of tumor burden assessed by appearance of
enhancement on contrast-enhanced T1-weighted images. This is
due to local breakdown of the BBB secondary to angiogenesis in
aggressive tumors (11). Response criteria developed by Macdon-
ald et al. (12) improved on previous radiologic assessments of
tumors, such as the World Health Organization response criteria,
by combining bi-directional measures of enhancing tumor burden
with clinical parameters, such as corticosteroid use and neurolog-
ical status (13). The Macdonald criteria classify response into four
categories: complete response (CR), partial response (PR; ≥50%
decrease in the sum of the products of perpendicular diameters
of all measurable enhancing lesions sustained for at least 4 weeks,
and stable or improved clinically), stable disease (SD), and PD
(≥25% increase in sum of products of perpendicular diameters of
enhancing lesion or clinical deterioration) (Table 1) (12).
Table 1 | Current response criteria for malignant gliomas (Macdonald
criteria).
Response Criteria
Complete
response
Requires all of the following: complete disappearance of
all enhancing measurable and non-measurable disease
sustained for at least 4 weeks, no new lesions, no
corticosteroids, and stable or improved clinically
Partial
response
Requires all of the following: ≥50% decrease compared
with baseline in the sum of products of perpendicular
diameters of all measurable enhancing lesions sustained
for at least 4 weeks, no new lesions, stable or reduced
corticosteroid dose, and stable or improved clinically
Stable
disease
Requires all of the following: does not qualify for complete
response, partial response, or progression; and stable
clinically
Progression Defined by any of the following: ≥25% increase in sum of
the products of perpendicular diameters of enhancing
lesions, any new lesion, or clinical deterioration
Reprinted with permission from Ref. (6).
In 2010, in an effort to improve radiographic response criteria
in an era of new biologicals and increasing need for guidelines
regarding patients enrolling in clinical trials, the Response Assess-
ment in Neuro-Oncology (RANO) Working Group proposed
updated response criteria for high-grade gliomas (6) (Table 2).
Increasingly, T2-weighted imaging had been incorporated into
clinical practice and is particularly useful in visualizing vaso-
genic edema, gliosis, chemoradiation-related treatment effects,
as well as evolving infiltrative and non-enhancing tumor in
an era of antiangiogenic therapies that directly alter BBB per-
meability (14) (Table 2). Another important advance of the
RANO criteria was addressing and defining pseudoresponse and
pseudoprogression (6).
PSEUDOPROGRESSION
The standard of care in glioblastoma treatment involves maximal
safe resection followed by radiation with adjuvant temozolomide
(5, 6). Within 3 months from end of radiation treatment, 20–30%
of patients show increased contrast enhancement that resolves
without changes in treatment on subsequent MRI scans (6).
This phenomenon termed “pseudoprogression” is likely related
to enhanced inflammation and disruption of the BBB caused by
radiation itself, potentially enhanced by concurrent temozolomide
use (6). While the pathophysiology of pseudoprogression remains
to be elucidated, it seems to be part of a spectrum of radiation-
related changes ranging from subacute radiographic changes to
late radionecrosis (15). Pseudoprogression has also been reported
in interstitial chemotherapy with carmustine-loaded polymers,
which is a therapeutic option in both newly diagnosed (16–18)
and progressive (19, 20) high-grade gliomas. In patients implanted
with carmustine wafers, there is a high incidence (up to 90%)
of cyst development near the surgical bed (21, 22) as well as a
transient increase in contrast enhancement and peri-cavity edema
within the first 2 months after wafer placement (23).
Failure to recognize pseudoprogression may lead to premature
discontinuation of effective adjuvant temozolomide chemother-
apy and inappropriate inclusion of these patients into trials for
progressive/recurrent glioma, resulting in falsely elevated RRs and
PFS (6). The RANO criteria attempt to address this problem
by excluding patients who “progress” during the first 12 weeks
Table 2 | Summary of the proposed RANO response criteria.
Criterion CR PR SD PD
T1 gadolinium enhancing disease None ≥50% ↓ <50% ↓ but <25% ↑ ≥25% ↑a
T2/FLAIR Stable or ↓ Stable or ↓ Stable or ↓ ↑a
New lesion None None None Presenta
Corticosteroids None Stable or ↓ Stable or ↓ NAb
Clinical status Stable or ↑ Stable or ↑ Stable or ↑ ↓a
Requirement for response All All All Anya
RANO, response assessment in neuro-oncology; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; FLAIR, fluid-attenuated
inversion recovery; NA, not applicable.
aProgression occurs when this criterion is present.
bIncrease in corticosteroids alone will not be taken into account in determining progression in the absence of persistent clinical deterioration.
Reprinted with permission from Ref. (6), License Number 3484960750851.
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post-chemoradiation from entry into new clinical trials unless the
progression is largely outside the radiation field or if there is patho-
logic conformation of progressive/recurrent tumor (6). Despite
these advances, pseudoprogression remains a significant diagnos-
tic challenge, and this review will discuss the advanced imaging
techniques that are currently being evaluated in differentiating
pseudoprogression from true progression of glioblastoma.
ADVANCED IMAGING TECHNIQUES FOR EVALUATION OF
TREATMENT RESPONSE
DIFFERENTIATING PSEUDOPROGRESSION FROM TUMOR
PROGRESSION
Magnetic resonance perfusion imaging
The hemodynamic characteristics of brain tumors and radiation
necrosis can be estimated non-invasively using perfusion imag-
ing techniques. Three magnetic resonance perfusion techniques
are increasingly available on clinical MRI scanners: dynamic
susceptibility contrast (DSC)-MRI, dynamic contrast enhanced
(DCE)-MRI, and arterial spin labeling (ASL).
Dynamic susceptibility contrast-magnetic resonance imaging
Dynamic susceptibility contrast-magnetic resonance imaging
measures the signal intensity change related to T2/T2* relaxation
during a first-pass bolus of paramagnetic contrast agent (24, 25).
Quantitative parameters derived from the time–intensity curve
using normal brain as reference are used to depict pathological
alterations. These include relative cerebral blood volume (rCBV),
the most commonly studied parameter in DSC-MRI for charac-
terization brain tumor (Figure 1), as well as relative peak height
(rPH) and percentage of signal intensity recovery (PSR) (26).
These parameters can be normalized or standardized using nor-
mal gray and white matter for easier comparison between studies
and patients (27, 28).
While a number of studies have applied DSC-MRI meth-
ods to distinguish pseudoprogression from tumor progression in
glioblastoma, a wide range of sensitivity and specificity have been
reported (29–34). These variations can result from small sample
sizes in some of these studies as well as from differences in acquisi-
tion protocols, analytic techniques, and reference standards among
the studies. Using histopathology from 57 patients as a reference
standard, Barajas et al. demonstrated that rPH and rCBV were
significantly greater in progressive/recurrent tumor as compared
to radiation necrosis, while PSR values were significantly lower in
patients with recurrent tumor (30). rPH also appears to be the
best predictor of recurrent tumor compared to rCBV and PSR in
this study, since the latter two parameters have significant overlaps
between tumor tissue and radiation necrosis. Similarly, Hu et al.
examined 40 stereotactic specimens from 13 patients and com-
pared them with preoperative rCBV (31). With an rCBV threshold
of 0.71, pseudoprogression can be differentiated from progres-
sive/recurrent tumor with a sensitivity of 91.7% and a specificity
of 100% in this small series.
The role of histopathology as the standard reference for assess-
ment of tumor progression versus radiation necrosis is increas-
ingly being challenged; in addition to sampling error and reader
variability, post-treatment tissues often contain both viable tumor
and necrotic tissues making it difficult for all-or-none diagnoses.
On the other hand, imaging approaches that take into account
whole-tumor heterogeneity can mitigate this problem. Hu et al.
developed the concept of MRI-fractional tumor burden (pMRI-
FTB) and demonstrated that this parameter correlated with the
relative histologic fraction of viable tumor and was also predic-
tive of OS (35). Analyzing perfusion maps from 79 patients with
glioblastoma, Baek et al. demonstrated that histogram analysis of
whole-tumor rCBV can help differentiate pseudoprogression from
tumor progression with sensitivity of 85.7% and a specificity of
89.2% (34).
Perfusion maps before and after chemoradiation therapy
can be analyzed simultaneously as parametric response maps
(34). A decrease in rCBV and rCBF on parametric response
maps, counter-intuitively, is more often observed with progres-
sive/recurrent tumor (36). Cao et al. also reported that a decrease
FIGURE 1 | A new enhancing lesion appeared around the resection cavity 1 month following completion of chemoradiation, without evidence of
elevated rCBV on DSC-MRI. The lesion continued to grow during the next 2 months but eventually decreased in size, consistent with pseudoprogression.
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in fractional tumor volume with low rCBV 1 week following radi-
ation was predictive of improved survival in 23 patients with
high-grade gliomas (37). From the same study, it appears that
the timing of rCBV measurement following radiation is impor-
tant, since a decrease in the fractional high-CBV tumor volume in
the third week versus in the first week following radiation was also
predictive of a longer survival outcome. Mangla et al. have shown
in 36 glioblastoma patients that an increased in percentage change
of rCBV (> 5%) after radiation and temozolomide was predictive
of 1-year survival with a sensitivity of 90% and a specificity of
60% (38).
While DSC-MRI has several advantages as a choice of perfusion
imaging technique including ease of implementation, rapid acqui-
sition, and an optimized signal-to-noise level, there are a number
of technical limitations. Due to its sensitivity to susceptibility, the
signal-to-noise level of DSC-MRI can be significantly reduced in
anatomical areas near the bone or air interface, as well as near
sites with significant blood products. The accuracy of rCBV can
also be affected by the presence of BBB disruption resulting in
T1-weighted leakage and T2/T2*-residual effects. The effect from
contrast leakage can lead to either overestimation or underestima-
tion of rCBV in tumors (39) (Figure 2). Several methods can be
implemented to minimize the effect of contrast leakage perme-
ability on rCBV calculation, including contrast preloading (40),
dual-echo acquisition (41), and modeling of transvascular trans-
fer constant (37, 42–45). Finally, blood-pool contrast agents, such
as ferumoxytol, can reduce leakage effect; in patients with glioblas-
toma following chemoradiation, Gahramanov et al. demonstrated
that rCBV calculated from DSC-MRI perfusion acquisition using
ferumoxytol is predictive of OS without the need of leakage
correction (46).
FIGURE 2 | New enhancing area in a patient with glioblastoma
following chemoradiation treatment, with pathologically confirmed
tumor progression. The uncorrected CBV map showed an apparently
lower blood volume relative to normal brain. Presence of significant leakage
is seen within the enhancing lesion as indicated by signal intensity curve
and leakage map. Following leakage correction, elevated cerebral blood
volume in the enhancing region is confirmed.
Dynamic contrast enhanced-magnetic resonance imaging
Dynamic contrast enhanced-magnetic resonance imaging tech-
niques can characterize vascular permeability by quantifying
movement of paramagnetic contrast agents crossing the BBB
using pharmacokinetic models (47–49). The most widely stud-
ied variables derived from DCE-MRI in brain tumor imaging are
Ktrans (transfer coefficient between the intra- and extravascular
spaces), Ve (extravascular, extracellular space), and Kep (trans-
fer constant from the extracellular, extravascular space into the
plasma) (48, 49). Compared to DSC-MRI, DCE-MRI is relatively
immune to susceptibility artifact and can more accurately account
for contrast agent leakage effect in the calculation of cerebral
blood volume. With T1-weighted image acquisitions, DCE-MRI
derived perfusions maps also have greater signal-to-noise ratio
and spatial resolution, although there is a need for longer imaging
acquisition time.
Several studies have applied DCE-MRI to differentiate tumor
progression from radiation necrosis (Figure 3). Larsen et al.
reported nearly 100% sensitivity and specificity using calculated
CBV, comparable to those determined by FDG-positron emis-
sion tomography (PET) on the same patients (50). Bisdas et al.
demonstrated significant greater Ktrans in progressive/recurrent
tumor lesions as compared to the radiation-induced necrotic sites
(P ≤ 0.0184). A Ktrans cutoff value higher than 0.19 showed 100%
sensitivity and 83% specificity for detecting progressive/recurrent
gliomas (51).
Despite the advantages of DCE-MRI, the pharmacokinetic
models for calculation of physiological parameters are typically
complex and require several assumptions, leading to difficulty in
standardization. Non-model-based methods are easier to imple-
ment and the resulting semiquantitative parameters, while not
physiologic, are more reproducible. Narang et al. assessed non-
model based parameters initial area under the signal intensity–
time curve (iAUC) and maximum slope of enhancement in
initial vascular phase (MSIVP) to help differentiate progres-
sive/recurrent glioblastoma from radiation necrosis in 36 patients
FIGURE 3 | A new enhancing lesion appeared adjacent to the resection
cavity 3 months following completion of chemoradiation (A), without
evidence of elevated kTrans (B) on DCE-MRI. The lesion remained
unchanged in size for the subsequent 4 months, consistent with
pseudoprogression.
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with glioblastoma (52). Significantly higher MSIVP and iAUC (at
60 and 120 s) were observed in the progressive/recurrent tumor
group, with MSIVP being the better single predictor with high
sensitivity (95%) and specificity (78%).
In a larger retrospective cohort of 169 patients with patho-
logically or clinicoradiologically diagnosed progressive/recurrent
glioblastoma (n= 87) or radiation necrosis (n= 82), Kim et al.
demonstrated the addition of either DSC-MRI or DCE-MRI to
contrast-enhanced T1-weighted and diffusion-weighted images
improved prediction of progressive/recurrent tumor (53). How-
ever, there was no significant difference between DSC-MRI and
DEC-MRI in the degree of improvement for diagnostic accuracy.
Arterial spin label MR perfusion
Arterial spin label (ASL) MR perfusion imaging estimates cere-
bral blood flow (CBF) by tagging endogenous blood as a flow
tracer without the need of injecting exogenous contrast (54, 55).
Although ASL is limited by lower signal intensity-to-noise ratio
and longer acquisition time compared to DCE-MRI and DSC-
MRI, the major advantage of ASL technique is its application in
patients with insufficient renal excretory function and the ability
to repeat ASL acquisitions during a single study. This technique
has been applied to imaging of glioma, and the blood flow mea-
surement correlates with histologic grades (56, 57). Choi et al.
retrospectively evaluated the added value of ASL to DSC-MRI
in 177 consecutive patients with glioblastoma following standard
chemoradiation therapy (58) (Figure 4). Among the 62 patients
who developed contrast-enhancing lesions, ASL grading is an
independent predictor of early tumor progression and improves
diagnostic accuracy when interpreted qualitatively in conjunction
with DSC-MRI.
The advantages and disadvantages of the three MR perfusion
techniques discussed in this review are summarized in Table 3.
The clinical value of perfusion imaging has been increasingly
recognized in neuro-oncology centers as recently demonstrated
by Geer et al. in their analysis of the contribution of perfu-
sion imaging to clinical decision making (59). While the acqui-
sition and analytic algorithms have improved significantly over
the last decade, for perfusion to be incorporated into standard
response criteria in clinical trials and routine clinical practice,
significant improvements are still needed in standardizing per-
fusion protocols in order to increase diagnostic accuracy and
reproducibility.
Magnetic resonance diffusion imaging
Magnetic resonance diffusion imaging can non-invasively exam-
ine tissue by probing microscopic water motion to indirectly assess
cell density and architecture. When applied to brain tumors, dif-
fusion imaging can assist in differentiating tumor type (60–64), as
well as predicting tumor grade (65–68) and estimating prognosis
(67). Most current clinical applications of diffusion imaging is per-
formed with diffusion weighting factor b near 1000 s/mm2 where
the diffusion signal decay is approximately mono-exponential.
This single exponential constant, or apparent diffusion coefficient
(ADC), can be readily calculated for each voxel and represented
as a magnitude map. In brain tumor imaging, ADC has been
shown to inversely correlate with tumor cell density (64, 65, 69).
With increased cellularity, ADC values tend to be lower for high-
grade glial tumors, likely due to restricted water motion in the
midst of tightly packed tumor cells (65). On the other hand, per-
itumoral edema is characterized by high ADC values (60, 70).
Other pathological conditions can also result in alterations in
ADC values including ischemia, infection or inflammation. Thus,
diffusion-weighted imaging is often interpreted alongside other
MR sequences to increase diagnostic specificity. One important
cause of new or increased enhancement following chemoradiation
is due to postsurgical infarction (71). Thus, examining diffusion-
weighted images of immediate postoperative MRI is important in
making this diagnosis.
Several prior studies have demonstrated lower ADC values with
respect to normal brain tissues in patients who received radiation
and chemotherapy and had subsequently confirmed tumor pro-
gression (72–74) (Figure 5). Furthermore, an increase in tumor
ADC values following therapy compared to pre-treatment ADC
has been shown to be predictive of favorable response (75, 76).
While the results from these studies with small patient sample
size support the value of diffusion MRI in differentiating pseudo-
progression from progressive/recurrent tumor, there are several
limitations that need to be considered when including this tech-
nique as part of diagnostic algorithm. First, variations in MRI
FIGURE 4 | A new enhancing lesion appeared along medial margin of right temporal resection cavity 2 months following completion of
chemoradiation (A), without evidence of neither elevated CBF on ASL perfusion (B), nor elevated rCBV (C) on DSC-MRI. The lesion was confirmed as
pseudoprogression on subsequent imaging.
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equipment and acquisition parameters can result in differences in
calculated ADC values, and even ratio values using normal appear-
ing brain as a reference can produce inconsistent results. This could
be one reason for a lack of consistent threshold values allowing for
differentiating tumor progression from necrosis. Second,ADC val-
ues within a single tumor are often heterogeneous, likely reflecting
a mixture of viable and necrotic tumor tissue as mentioned ear-
lier. Thus, ADC analyses using mean or median in tumor volume
of interest may not be sensitive to spatial heterogeneity, resulting
in inaccurate diagnosis of tumor progression. Histogram-based
Table 3 | Summary of MR perfusion imaging techniques.
Perfusion
technique
Advantages Disadvantages
Dynamic
susceptibility
contrast (DSC)
Short imaging time Prone to artifacts from
bone, metal and airMore widely available
Lower spatial resolution
Need leakage correction
Dynamic contrast
enhanced (DCE)
Higher spatial resolution Longer imaging time
Estimate vascular
permeability
Require pharmacokinetic
modeling
Arterial spin label
(ASL)
Quantifies blood flow Longer imaging time
Does not need contrast Lower signal-to-noise ratio
methods have been developed to characterize relative mixtures
of ADC values and tested as predictors of patient outcome (77,
78). While promising, implementation of this approach in rou-
tine practice remains challenging due to a requirement for tumor
volume segmentation but can be facilitated with automated or
semi-automated volume segmentation techniques.
Magnetic resonance spectroscopy
Magnetic resonance spectroscopy (MRS) can non-invasively mea-
sure concentrations of tissue metabolites and has shown promising
applications in evaluating brain tumors including their diagno-
sis, grading, pre-therapy planning, and post-therapy assessment
(79). MRS data can be acquired using single-voxel technique by
manually defining regions-of-interest within brain lesions, and
altered levels of several known metabolites including N -acetyl
aspartate (NAA), choline, creatine, and lactate provide a basis
for distinguishing suspected progressive/recurrent tumor from
treatment-related changes (80–83). While higher choline to crea-
tine and choline to NAA ratios were observed in tumor progression
compared to normal appearing brain or treatment necrosis, clas-
sification of tissues containing mixtures of tumor and necrosis
using single-voxel techniques can be challenging. A multi-voxel
acquisition approach (chemical shift imaging) can account for
spatial heterogeneity in tissues and appears to improve diagnos-
tic accuracy for detecting tumor (84–89). A recent meta-analysis
reported that the diagnostic performance in differentiating glioma
FIGURE 5 | Enlarging left parieto-occipital lobe enhancement 4 months
following chemoradiation therapy (A). The enhancing region demonstrated
low ADC (B) on DWI, mildly elevated rCBV (C) on DSC-MRI. FDG-PET (D) of
the same lesion had less conspicuous lesion to background uptake compared
to FLT-PET (E) and FET-PET (F). Subsequent resection confirmed
progressive/recurrent glioblastoma.
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progression from radiation necrosis using choline to NAA ratio
has sensitivity and specificity of 0.88 and 0.86, respectively (90).
In addition, biochemical changes during post-treatment necrosis
appear to have temporal variability, including decreased NAA con-
centrations over time and a transient increase in choline following
radiation therapy (80, 82, 86, 91, 92), suggesting that a longitudinal
evaluation using MRS may provide greater specificity.
While the diagnostic value of MRS in distinguishing progres-
sive/recurrent tumor from treatment-induced necrosis remains
to be validated, a number of challenges need to be addressed.
First, MRS acquisitions using either single- or multi-voxel meth-
ods require manual input for selecting region-of-interest and
placement of saturation bands, thereby introducing variability
dependent on user experiences. The relative lower spatial res-
olution of MRS compared to conventional imaging sequences
can introduce uncertainty during spectral acquisitions due to
inclusion of non-lesional tissues, such as normal brain, surgical
cavity, or subarachnoid spaces, requiring expert review of con-
ventional sequences when interpreting MRS findings. Finally, MR
equipment, pulse sequences, parameters, and data post-processing
methods can also affect measurement reproducibility across treat-
ment sites. These technical challenges are important to over-
come for standardization and implementation of this promising
technique.
Positron emission tomography
Compared to normal brain tissues, tumors often carry greater
metabolic activity, which can be detected by PET imaging as
increased uptake of 18F-fluorodeoxyglucose (18F-FDG), a radio-
labeled glucose analog (93). For primary brain neoplasms, the
degree of 18F-FDG uptake on PET has been correlated with both
tumor grade (94, 95) and patient survival (96–102).
18F-Fluorodeoxyglucose PET has also become a valuable tool
for assessing treatment response in a number of human can-
cers (103). Several previous studies have examined the utility of
FDG-PET in distinguishing radiation necrosis from tumor fol-
lowing radiation treatment, with a broad range of sensitivities and
specificities reported (104–108). However, most of the patients
included in these studies developed lesions with new or increased
enhancement on MRI more than 3 months after therapy, while the
majority of patients with pseudoprogression experience imaging
findings within the first 3 months after chemoradiation. Thus, the
results from the application of FDG-PET imaging techniques in
delayed post-radiation necrosis and tumor progression may not
be directly translated to its ability to distinguish between the sub-
acute post-radiation changes (i.e., pseudoprogression) and true
tumor progression. Furthermore, the use of FDG-PET in assess-
ment of tumor progression is limited by a number of factors.
First, due to the relative intrinsic high metabolism in normal brain
cortex, measurement of FDG uptake within lesions near gray mat-
ter can be difficult. While delayed phase FDG-PET imaging may
improve discrimination between glioma and normal gray mat-
ter, evidence supporting its use remains preliminary (109, 110).
Second, the sensitivity of FDG-PET in determining tumor pro-
gression can be limited by the intrinsic changes of recurrent tumor
affecting FDG-PET uptake; while high-grade gliomas tend to be
hypermetabolic on FDG-PET (111), the level of FDG uptake of
progressive/recurrent tumor may differ from that of the original
tumor. Third, radiation necrosis may be associated with inflam-
matory processes and increased glucose metabolism (112), making
elevation of FDG uptake less specific in this setting. Finally, the
resolution of PET imaging is currently limited to 5 mm. While co-
registration with CT and PET on dedicated scanners can improve
accuracy of lesion localization, detection and assessment of small
lesions in the setting of early recurrence remains difficult. Despite
these limitations, FDG-PET imaging has become widely available
in major cancer centers, making this an important diagnostic tool
for detecting tumor recurrence when combined with advanced
MR imaging.
Amino acid PET
The short-coming of the relatively low tumor-to-background FDG
uptake prompts investigations of other tumor-sensitive radiotrac-
ers with intrinsically low accumulation by normal brain tissues.
In malignant brain tumors, higher proliferative activities in neo-
plastic cells result in increased amino acid transport (113–116),
providing a basis for using radio-labeled amino acids as target
for brain tumor in PET imaging. Due to relative slow uptake of
amino acid in normal brain, amino acid radiotracer has the impor-
tant advantage of high lesion-to-background uptake for imaging
of brain tumors (Figure 5).
l-Methyl-11C-methionine (11C-MET) is the most widely
characterized amino acid radiotracer in imaging of brain tumors
(117–120). Compared to FDG, 11C-MET PET is superior in
detecting tumor progression (121, 122), even in cases where there
is normal or low FDG uptake by tumors (123). Other C11 based
radiotracers also have shown similar promising results, includ-
ing l-1-[11C]-tyrosine (11C-TYR) (124–126). However, due to
the relatively short half-life of 11C, clinical application of 11C-
MET and 11C-TYR require on-site cyclotrons and their current
availability remains quite limited.
Amino tracers with longer half-life radiolabel include
3′-fluoro-3′-deoxy-l-thymidine (18F-FLT) (127–130), O-2-18
F-fluoroethyl-l-tyrosine (18F–FET) (131–135),and 3,4-dihydroxy-
6-[18F]-fluoro-l-phenylalanine (18F-FDOPA) (136–141). These
tracers all share the same features of lower normal cortical tracer
uptake and facilitate clinical implementation due to the longer
half-life of F18. Furthermore, kinetic modeling of radiotracer
uptake may provide additional specific markers that can distin-
guish between tracer uptake due to BBB leakage, such as the case of
radiation necrosis, and tracer accumulation due to increased active
transport in growing tumors (129, 130). While preliminary results
identify these radiotracers as early markers of treatment response
and survival, (141–144), their roles in distinguishing treatment-
related changes from true progressive/recurrent tumor remain to
be validated in larger prospective trials.
Antiangiogenic therapy and pseudoresponse
Direct correlation of enhancing disease burden with glioma pro-
gression is particularly challenging in the context of antiangio-
genic therapies targeting vascular endothelial factor (VEGF), such
as bevacizumab, a recombinant humanized monoclonal anti-
body to VEGF-A, or the VEGF receptor such as cediranib, a
pan-VEGF receptor tyrosine kinase inhibitor (6, 145). Through
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normalization of leaky tumor blood vessels, these agents can cause
reduction in enhancement within 1–2 days after administration,
with a radiographic response in 25–60% of patients (146). This
impressive radiographic response unfortunately does not translate
into increased survival. It is thought that this rapid radiographic
response represents a direct action on blood vessel permeabil-
ity rather than a true anti-tumor effect; a phenomenon termed
“pseudoresponse” (6, 147). The RANO criteria address this issue
by requiring a radiographic response to persist for more than
4 weeks in order to be considered a true response (6, 147). A fur-
ther confounder in radiographic assessment of response is the
tendency for antiangiogenic agents to promote progression of
non-enhancing disease by selecting for an invasive tumor phe-
notype capable of co-opting existing blood vessels and no longer
relying on angiogenesis (6, 147). T2-weighted or FLAIR images
best represent infiltrative disease. The radiographic appearance
of infiltrative tumor is often subtle and diverse, including evi-
dence of mass effect and invasion of the cortical ribbon. Given the
radiographic variability of non-enhancing infiltrative disease, the
RANO group concluded current technologies fell short of pro-
viding objective measures of infiltrative tumor progression (6).
Since progression of infiltrative tumor often causes clinical dete-
rioration, the RANO criteria include the patient’s clinical status
in assessment of progressive non-enhancing tumor (6). Clearly,
this is a suboptimal imaging surrogate and highlights the acute
need for superior technologies in assessment of non-enhancing
tumor progression. Here, we review promising advanced imaging
modalities for the assessment of tumor burden in the context of
antiangiogenic therapy.
DETECTING TUMOR IN ANTIANGIOGENIC THERAPY
T1 subtraction map
Due to their effect on vascular permeability, antiangiogenic agents
result in a dramatic reduction in contrast enhancement within
tumor on T1-weighted images soon after initiation of therapy
that is unrelated to anti-tumor effect. While the relative reduc-
tion in enhancement can be interpreted as non-enhancement by
visual analyses, quantitative methods using voxel-to-voxel image
subtraction between T1-weighted images before and after con-
trast administration may detect subtle residual enhancement and
therefore provide a more accurate and reproducible assessment
of true tumor extent in the context of antiangiogenic treatment
(148, 149). Recently, Ellingson et al. analyzed 160 patients from
the phase II randomized clinical trial (AVF3708g, BRAIN trial)
in patients with glioblastoma treated with bevacizumab or beva-
cizumab and irinotecan using a T1 subtraction method (150).
There was significantly improved visualization and quantification
of tumor volume in post-treatment patients and calculated brain
volume from subtracted images correlated with both PFS and
OS better than those from un-subtracted post-contrast images.
This method can be readily incorporated into clinical practice
since pre and post-contrast T1-weighted imaging are usually part
of standard protocol in brain tumor imaging, although ease-of-
use post-processing software for co-registration, normalization,
and subtraction are necessary. Additional technical challenges also
include the need of standardizing image acquisition to minimize
inter-subject and intra-subject variability.
T2 mapping
While evaluation of T2/FLAIR disease in the setting of antian-
giogenic therapy has been incorporated into the RANO criteria
and increasingly adopted in recent clinical trials, the assessment
is based on qualitative inspection without any objective guide-
lines. This is in part due to difficulties measuring T2/FLAIR
disease with consistency and the lack of specificity for tumor tis-
sues versus other cause of T2/FLAIR signal abnormality including
edema, necrosis, and gliosis. T2 mapping is an imaging tech-
nique that quantifies T2 relaxation for each voxel using the
effective echo times from two echoes acquired during a fast-
spin echo preparation. Using this method, Ellingson et al. was
able to perform direct voxel-to-voxel subtraction of quantita-
tive maps before and after bevacizumab treatment in patients
with glioblastoma (151). The resulting maps allowed visualiza-
tion and quantification of voxel-wise T2 changes resulting from
anti-VEGF therapy (Figure 6). There was a significant decrease
in T2 relaxation time within pre-treatment T2 abnormal regions
following treatment, and an elevated residual, post-treatment; in
addition, median T2 was predictive of both PFS and OS. Hattin-
gen et al. extended the application of this technique to generate
longitudinal differential T2 maps using the first post-treatment
T2 map as a reference, and demonstrated non-enhancing tumor
progression more clearly than conventional T2-weighted imag-
ing (152). While the utility of T2 mapping techniques needs
to be validated with further studies, this technique is promising
both as an early post-treatment predictor and as a more sensitive
marker of non-enhancing tumor progression in antiangiogenic
therapy.
Diffusion MRI in antiangiogenic therapy
Unlike contrast-enhanced T1-weighted imaging, diffusion imag-
ing based on ADC analyses is relatively unaffected by alterations
in vascular permeability during antiangiogenic therapy (153).
This advantage makes it a potentially more accurate technique
in assessing the extent of tumor in this treatment setting.
A number of studies have evaluated the predictive value
of pre-treatment ADC values for both treatment response
and survival outcome. Due to heterogeneity of ADC values
within tumor regions, whole-tumor histogram analyses have
been increasingly utilized for evaluating the effect of different
ADC subcomponents that have different prognostic or predic-
tive values. Pope et al. applied histogram analyses of ADC val-
ues within contrast-enhancing progressive/recurrent glioblastoma
before bevacizumab treatment and demonstrated that the mean
value of the lower component of a two-Gaussian histogram fitting
is a predictor of PFS (154). This result was subsequently validated
using imaging data from a multicenter trial of patients with pro-
gressive/recurrent glioblastoma treated with bevacizumab with or
without irinotecan, and the pre-treatment lower ADC compo-
nent of enhancing regions was associated with OS (155). The
pre-treatment ADC histogram of non-enhancing T2/FLAIR in
91 patients with progressive/recurrent glioblastoma also has been
characterized using a four-component fitting model, and the resul-
tant low to middle peak ratio was shown to be a predictor of OS
independent of both the extent of the enhancing region and tumor
size (156).
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FIGURE 6 | Differential quantitativeT2 maps. Reprinted with permission from Ref. (151), License Number 3520001314812. More apparent changes on the
differential T2 map (bottom row) in the left frontal lobe (arrows) compared to T2-weighted images (top row). These changes are hardly visible on conventional
T2-weighted images (arrows).
Treatment-induced changes in ADC obtained by comparing
pre- and early post-treatment measurements have also been tested
as an imaging marker of treatment outcome. Nowosielski et al.
examined the skewness, or degree of asymmetry, of ADC his-
tograms in patients with progressive/recurrent glioblastoma and
showed that patients with increasing skewness (n= 11) follow-
ing bevacizumab/irinotecan therapy had significantly shorter PFS
than did patients with decreasing or stable skewness (157). While
histogram-based approaches can analyze the relative proportion of
individual ADC subtypes, regional changes before and after ther-
apy cannot be captured. Using functional diffusion map (fDM)
methods by voxel-wise subtraction of pre- and post-treatment
ADC maps, precise magnitude of change in ADC at all tumor
locations can be studied. Ellingson et al. (158, 159) applied a
graded fDM using multiple thresholds of ADC change to assess
antiangiogenic therapy in progressive/recurrent glioblastoma and
showed that the volume of decreased ADC values between 0.25
and 0.40µm2/ms in both enhancing and non-enhancing regions
is associated with OS.
Change in ADC can also be followed longitudinally by serial
MRI. Using percentage change of low ADC volume over time,
Gerstner demonstrated progressive increase of percent volume
with low ADC volume within non-enhancing regions following
cediranib therapy to correlate with infiltrative tumor progres-
sion (160). Similarly, Jain et al. compared mean ADC within
contrast-enhancing and non-enhancing volumes and determined
that patients with PD showed a sequential increase in the nega-
tive percent change of ADC values following bevacizumab therapy
(161). While ADC values can correlate with tumor growth in serial
imaging, developing automated methods of voxel-wise subtrac-
tion is important for real-time adoption of this method for use in
prospective clinical trials.
High b-value MR diffusion imaging
In most commonly used clinical MR scanners, the b value of dif-
fusion gradient is usually 1000 s/mm2. When the b value increases
to beyond 3000 s/mm2, diffusion signal decay is no longer mono-
exponential, and analysis of higher range b values potentially can
result in greater imaging contrast between different tissue types.
Applying high b-value diffusion imaging to characterize brain
tumors, Seo et al. demonstrated that the degree of ADC decrease
was greater in tumors compared with normal brain tissue (162).
Using histogram analysis of ADC maps based on entire tumor
volume, Kang et al. demonstrated that the histogram parame-
ters derived from high b values performed better diagnostically
than those from standard b values in differentiating high- from
low-grade gliomas. ADC values decreased when the b value was
increased from 1000 to 3000 s/mm2, and a greater decrease was
observed with higher tumor grades (163). In 4 of 10 patients with
progressive/recurrent glioma treated with bevacizumab, high b-
value diffusion imaging identified pseudoresponse at earlier times
compared to both the Macdonald and RANO criteria (164).
MR perfusion imaging
The ability of perfusion imaging techniques to measure blood
flow dynamics in vivo makes them potentially useful tools not
only for understanding the effect and mechanism of antiangio-
genic therapy, but also for providing prognostic or predictive
information important for patient selection and treatment deci-
sions. While mechanisms of action of antiangiogenic agents are not
fully understood, early decrease in Ktrans, an DCE-MR marker
of vascular permeability (49), can be detected at day 1 after a
single dose of cediranib in patients with progressive/recurrent
glioblastoma, and the decrease has been shown to be associated
with improved PFS and OS (146, 165). The improved blood flow
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was also associated with tumor oxygenation (166). These obser-
vations support the theory of “vascular normalization” as the
mechanism of action (167), and a “vascular normalization index”
(VNI) combining Ktrans and circulating collagen IV were subse-
quently proposed as a marker to predict survival (165). A similar
VNI parameter can be obtained by comparing pre-treatment and
1-day post-treatment DSC-MRI using a single double-echo acqui-
sition. This new VNI parameter combining changes in tumor CBV
and an apparent transfer constant (Ka) using a leakage correction
method was predictive of PFS and OS in 30 patients with progres-
sive/recurrent glioblastomas enrolled in a phase II clinical trial of
an oral pan-VEGF receptor tyrosine kinase inhibitor (45).
Using DSC-MRI, Essock-Burns examined 35 patients with
newly diagnosed GBM who received temozolomide chemoradio-
therapy with enzastaurin, an oral PKC isoform kinase inhibitor,
after surgical resection (168). Responders at 6 months showed an
increased percent recovery (PR) between baseline and 2 months
into therapy, indicating improved permeability, whereas non-
responders at 6 months showed significantly increased peak height
(PH), a marker of microvascular density similar to CBV (169)
between baseline and 1 month. Using standardized rCBV, a con-
sistent intensity scale regardless of MR scanner model or field
strength, Schmainda et al. examined the prognostic values of DSC-
MRI findings in 36 patients with progressive/recurrent high-grade
glioma 60 days before and 20–60 days after starting bevacizumab
and reported longer OS if pre- or post-treatment standardized
rCBV is less than 4400 (170). The use of standardized perfusion
parameters can reduce variability when comparing findings from
different subjects, scanners, or using different acquisition tech-
niques, but the reported threshold values require validation in
larger clinical data sets.
Evaluating treatment response to immunotherapy
A newer challenge is the differentiation of pseudoprogression from
true progression in patients who receive immunotherapy. The FDA
approval of two recent immunotherapy approaches, Sipuleucel-T
(APC8015) for prostate cancer and ipilimumab for melanoma,
as well as ongoing trials showing efficacy of immunotherapy
against challenging cancers, heralds a new era of cancer treat-
ment (171, 172). Ongoing immunotherapy trials in glioblastoma
hold great promise for improved outcomes in this devastating ill-
ness (171, 172). Since the goal of immunotherapy is to harness
the patient’s immune system to fight cancer, inflammation in the
tumor bed is expected much more than with cytotoxic chemother-
apies. Experience in melanoma trials has shown that while tumor
regression is often low (only 10% of patients), many patients can
have prolonged periods of stability (173). This would potentially
go undetected using RR as an endpoint (173–175). In addition,
some tumors may develop new lesions or transiently increased
size before eventually becoming smaller. To re-define response
in the context of immunotherapy, assess efficacy of treatment in
clinical trials, prevent patients from discontinuing a potentially
beneficial treatment, as well as to ensure that patients do not
remain on a potentially harmful, ineffective treatment, Wolchuk
FIGURE 7 | A patient with progressive glioblastoma treated by
immunotherapy including nivolumab (anti-PD1antibody) and
ipilimumab (anti-CTLA-4 antibody). There was a transient increase in
enhancing area in the posterior corpus callosum and left corona radiation
24 weeks following therapy initiation, consistent with pseudoprogression.
Week 32 imaging was obtained after 1 week of corticosteroid therapy.
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et al. proposed a new set of response criteria termed immune-
related response criteria (irRC) for melanoma (173). The irRC
allow for patients tolerating therapy to stay on treatment beyond
initial progression for another 4 weeks and define disease progres-
sion as an increase in the measurement of overall tumor burden
rather than the appearance of new lesions (173, 176).
Ongoing immunotherapy trials for glioblastoma also show
complex radiographic effects, including inflammation leading
to the enlargement of pre-existing enhancing lesions or the
appearance of new enhancing lesions (Figure 7). It is particularly
challenging given current technologies to differentiate pseudo-
progression caused by an anti-tumor mediated immune response
from true progression using the RANO criteria, as timing of
immune-mediated anti-tumor effects seems to differ from that
seen with cytotoxic chemotherapies (173, 177, 178). The mech-
anism of contrast enhancement during pseudoprogression fol-
lowing immunotherapy is presently unclear and may be different
from that following traditional chemoradiation therapy. Current
efforts are ongoing to incorporate immune-related considerations
into the RANO criteria (iRANO) to allow for improved response
assessment and provide clinical guidelines for patients undergoing
immunotherapy trials for glioblastoma. The iRANO criteria will
define PD as persisting beyond a determined period of time after
initial radiographic evidence of progression, allowing for patients
with no significant neurological decline to stay on a potentially
efficacious treatment longer and also allow for discontinuation of
treatment earlier in the context of significant neurological decline.
While iRANO criteria are currently being developed, advanced
neuroimaging modalities useful in differentiating pseudoprogres-
sion from true progression may become invaluable in making
clinical decisions in this rapidly evolving field of immunotherapy.
To date, only a few studies have evaluated advanced imag-
ing techniques in characterizing pseudoprogression following
immunotherapy. Vrabec et al. retrospectively assessed MR per-
fusion and diffusion imaging findings of eight patients with pro-
gressive/recurrent glioblastoma following dendritic cell immune
therapy. In this small series, contrast-enhancing areas secondary
to immune therapy-induced inflammation showed significant dif-
ferences in maximum rCBV ratios and minimum ADC values
compared to progressive/recurrent tumor (179). With a grow-
ing number of immunotherapy-based clinical trials for malignant
glioma, the clinical and imaging characteristics of pseudoprogres-
sion with respect to each type of immunotherapy ultimately will
become better understood. Most importantly, there is an urgent
need to explore, validate, and standardize radiographic criteria
based on both available and new imaging techniques for patients
receiving immunotherapy in order to better define treatment
efficacy.
CONCLUSION
The updated criteria proposed by the RANO group have incor-
porated new guidelines to address the phenomena of pseudopro-
gression and pseudoresponse in patients with high-grade glioma.
A minimum standard protocol necessary for evaluating radi-
ographic response per RANO criteria should consist of pre-
and post-contrast T1-weighted sequence as well as T2 and/or
FLAIR sequences, ideally with the same magnetic field strength,
acquisition parameters, and contrast dose throughout baseline
and subsequent follow-up MRI studies to improve measurement
reproducibility. The time interval between MRI studies imme-
diately following radiation treatment is typically 1 month unless
new clinical symptoms mandate earlier imaging. Advanced MRI
sequences, such as perfusion and diffusion-weighted imaging, are
also recommended as part of a standard imaging protocol to
be readily evaluated in conjunction with conventional sequences
when tumor progression or post-treatment changes are suspected.
Other imaging techniques, such as MRS and PET, may help eval-
uate suspected lesion(s) and may require referral to centers with
expertise in neuroimaging as well as neuro-oncology care.
With a growing number of new therapeutic options available
for glioblastoma patients, diagnostic imaging tools allowing accu-
rate characterizations of tumor response or resistance are urgently
needed. We reviewed a number of advanced imaging methods for
evaluating pseudoprogression following standard chemoradiation
therapy and clinical trials including immunotherapy, as well as
pseudoresponse in the setting of antiangiogenic therapy. As these
techniques are increasingly incorporated into routine brain tumor
imaging protocols, the sensitivity and specificity for detecting true
tumor growth or shrinkage will be better defined. These advances
should come with an emphasis on standardization and ease of
implementation, which are required for subsequent validation and
clinical use.
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